Literature DB >> 20497599

Is fibrinogen the answer to coagulopathy after massive transfusions?

Samuel A Tisherman1.   

Abstract

Coagulopathy is a major cause of morbidity and mortality in patients who have suffered severe hemorrhage and received massive transfusions. Administration of a fibrinogen concentrate along with red blood cells can quickly restore hemostasis in a clinically relevant animal model.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20497599      PMCID： PMC2911703          DOI： 10.1186/cc9000

Source DB:  PubMed          Journal:  Crit Care        ISSN： 1364-8535            Impact factor:   9.097


  13 in total

1.  Pharmacokinetic properties of a pasteurised fibrinogen concentrate.

Authors:  Wolfhart Kreuz; Esther Meili; Kristiina Peter-Salonen; Alena Dobrkovská; Jan Devay; Sabine Haertel; Udo Krzensk; Rudolf Egbring
Journal:  Transfus Apher Sci       Date:  2005-06       Impact factor: 1.764

2.  Fibrinogen concentrate substitution therapy in patients with massive haemorrhage and low plasma fibrinogen concentrations.

Authors:  C Fenger-Eriksen; M Lindberg-Larsen; A Q Christensen; J Ingerslev; B Sørensen
Journal:  Br J Anaesth       Date:  2008-09-25       Impact factor: 9.166

3.  Effects of different fibrinogen concentrations on blood loss and coagulation parameters in a pig model of coagulopathy with blunt liver injury.

Authors:  Oliver Grottke; Till Braunschweig; Dietrich Henzler; Mark Coburn; Rene Tolba; Rolf Rossaint
Journal:  Crit Care       Date:  2010-04-14       Impact factor: 9.097

4.  Blood transfusion, independent of shock severity, is associated with worse outcome in trauma.

Authors:  Debra L Malone; James Dunne; J Kathleen Tracy; A Tyler Putnam; Thomas M Scalea; Lena M Napolitano
Journal:  J Trauma       Date:  2003-05

5.  Hemostatic changes after crystalloid or colloid fluid administration during major orthopedic surgery: the role of fibrinogen administration.

Authors:  Markus Mittermayr; Werner Streif; Thorsten Haas; Dietmar Fries; Corinna Velik-Salchner; Anton Klingler; Elgar Oswald; Christian Bach; Mirjam Schnapka-Koepf; Petra Innerhofer
Journal:  Anesth Analg       Date:  2007-10       Impact factor: 5.108

6.  Prophylactic fibrinogen infusion reduces bleeding after coronary artery bypass surgery. A prospective randomised pilot study.

Authors:  Martin Karlsson; Lisa Ternström; Monica Hyllner; Fariba Baghaei; Agneta Flinck; Stanko Skrtic; Anders Jeppsson
Journal:  Thromb Haemost       Date:  2009-07       Impact factor: 5.249

7.  Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial.

Authors:  C Fenger-Eriksen; T M Jensen; B S Kristensen; K M Jensen; E Tønnesen; J Ingerslev; B Sørensen
Journal:  J Thromb Haemost       Date:  2009-03-05       Impact factor: 5.824

8.  A reduction in clot formation rate and strength assessed by thrombelastography is indicative of transfusion requirements in patients with penetrating injuries.

Authors:  Amy J Plotkin; Charles E Wade; Donald H Jenkins; Kimberly A Smith; Jody C Noe; Myung S Park; Jeremy G Perkins; John B Holcomb
Journal:  J Trauma       Date:  2008-02

9.  Transfusion of fresh frozen plasma in critically ill surgical patients is associated with an increased risk of infection.

Authors:  Babak Sarani; W Jonathan Dunkman; Laura Dean; Seema Sonnad; Jeffrey I Rohrbach; Vicente H Gracias
Journal:  Crit Care Med       Date:  2008-04       Impact factor: 7.598

10.  The ratio of fibrinogen to red cells transfused affects survival in casualties receiving massive transfusions at an army combat support hospital.

Authors:  Harry K Stinger; Philip C Spinella; Jeremy G Perkins; Kurt W Grathwohl; Jose Salinas; Wenjun Z Martini; John R Hess; Michael A Dubick; Clayton D Simon; Alec C Beekley; Steven E Wolf; Charles E Wade; John B Holcomb
Journal:  J Trauma       Date:  2008-02
View more
  1 in total

1.  Prevalence, predictors and outcome of hypofibrinogenaemia in trauma: a multicentre observational study.

Authors:  Jostein S Hagemo; Simon Stanworth; Nicole P Juffermans; Karim Brohi; Mitchell Cohen; Pär I Johansson; Jo Røislien; Torsten Eken; Paal A Næss; Christine Gaarder
Journal:  Crit Care       Date:  2014-03-26       Impact factor: 9.097
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.